

DATE:	2021 March 22
TO:	Central and South Zones: Physicians, Laboratory Directors, Managers, and Supervisors
FROM:	Clinical Biochemistry, South Sector, Alberta Precision Laboratories (APL)
RE:	Changes to Lower Reportable Limit of Digoxin

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- Effective **March 23, 2021**, the lower reportable limit for digoxin will be changed to **<0.30 nmol/L** from <0.1 nmol/L.

Why This is Important:

- Due to unknown interference a weak positive signal was detected on the Siemens Vista analyzers used in South and Central Zones to determine digoxin concentration in the plasma.
- The lower reportable limit for digoxin is being increased to avoid confusion caused by false-positive digoxin levels at sub-therapeutic range of drug concentrations.

Action Required:

- Be aware of the changes in the lower reportable limit of digoxin.

Inquiries and feedback may be directed to:

- Yury Butorin, PhD, Clinical Biochemist, Central Zone / Red Deer Regional Hospital, 403-406-5633, Yury.Butorin@aplabs.ca
- Dennis Orton, PhD, Clinical Biochemist, South Zone / Chinook Regional Hospital, 403-770-3219, Dennis.Orton@aplabs.ca

This bulletin has been reviewed and approved by:

- Heidi Paulin, MD, Regional Laboratory Medicine Site Chief for Red Deer Regional Hospital
- Krishna Narra, MD, Regional Laboratory Medicine Site Chief for Chinook Regional Hospital
- Hossein Sadrzadeh, PhD, Section Chief, Clinical Biochemistry, South Sector
- Ethan Flynn, MD on behalf of Leland Baskin, MD, Associate Medical Director, South Sector